OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kelly on Phase Ib Study of Reolysin Plus Bortezomib in Multiple Myeloma

February 11th 2017

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine discusses reolysin plus bortezomib (Velcade) in paitents with multiple myeloma.

Dr. Levine on Simulation in the Management of EGFR-Mutated Advanced NSCLC

February 11th 2017

Stacie Levine, MD, associate professor of Medicine, Director, Geriatrics and Hospice and Palliative Medicine Fellowship Program, The University of Chicago Medicine, discusses a trial regarding simulation in the management of EGFR-mutated advanced NSCLC

Dr. Neal on Ongoing Trials of Immunotherapy for Lung Cancer

February 11th 2017

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses ongoing trials in immunotherapy for patients with lung cancer.

Dr. Kumar on Next Steps for Venetoclax in Multiple Myeloma

February 10th 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the next steps for venetoclax (Venclexta) in the treatment of patients with multiple myeloma.

Dr. Loaiza-Bonilla on Trial of Left- and Right-Sided Colorectal Cancer

February 9th 2017

Arturo Loaiza-Bonilla, MD, medical oncologist, specializing in gastrointestinal malignancies, assistant professor of Clinical Medicine at the University of Pennsylvania, discusses a clinical trial focused on the differences between left- and right-sided tumors of colorectal cancer (CRC).

Dr. Ku on Immunotherapy in Gastric and Esophageal Cancer

February 9th 2017

Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center discusses immunotherapy treatments for patients with gastric and esophageal cancers.

Dr. Tjan-Heijnen on Results of DATA Study in Breast Cancer

February 9th 2017

Vivianne Tjan-Heijnen, MD, PhD, professor, Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center, discusses the results of the phase III DATA study.

Dr. Mutti on Current Role of Immunotherapy for Mesothelioma

February 9th 2017

Luciano Mutti, MD, professor of Cancer Research, University of Salford Manchester, discusses the current role of immunotherapy for patients with mesothelioma.

Dr. Goy on Impact of Lenalidomide on MCL Treatment

February 9th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the impact lenalidomide (Revlimid) has had on the treatment paradigm of mantle cell lymphoma (MCL).

Dr. Shuch on Biology of Non-Clear Cell RCC

February 9th 2017

Brian M. Shuch, MD, assistant professor of Urology and of Radiology and Biomedical Imaging, Yale Cancer Center, discusses the biology of non-clear cell renal cell carcinoma (RCC).

Dr. White On RTOG 1119 Trial for Breast Cancer

February 9th 2017

Julia White, MD, professor of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, discusses RTOG-1119 trial for patients with breast cancer.

Dr. Albala on Patient Selection for Robotic Surgery in Prostate Cancer

February 9th 2017

David Albala, MD, urologist and medical director, Associated Medical Professionals, discusses patients with prostate cancer who are best suited to be treated with robotic surgery.

Dr. Jackson on the Toxicity Profile of Lenalidomide Maintenance in Myeloma

February 9th 2017

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses the toxicity profile of lenalidomide maintenance therapy in the treatment of patients with multiple myeloma.

Dr. Nangia on Challenges Facing Hair Loss Treatment for Breast Cancer

February 8th 2017

Julie R. Nangia, MD, assistant professor, Breast Center-Clinic, faculty senator, Baylor College of Medicine, discusses hair loss prevention treatment for patients with breast cancer.

Dr. Scher on Promise of Liquid Biopsies in Prostate Cancer

February 8th 2017

Howard I. Scher, MD, chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential that liquid biopsies will have in the treatment landscape of prostate cancer.

Dr. Drilon on RET Rearrangements in NSCLC

February 8th 2017

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses RET rearrangements for patients with non–small cell lung cancer (NSCLC).

Dr. Reeder on Future Treatment Approaches in Aggressive Lymphomas

February 8th 2017

Craig B. Reeder, MD, assistant professor of Medicine, Mayo Clinic, discusses some future treatment approaches for patients with aggressive lymphomas, including diffuse large B-cell lymphoma.

Dr. Socinski on Recent Setbacks in Immunotherapy Combinations in NSCLC

February 7th 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses recent setbacks in immunotherapy combinations in non–small cell lung cancer (NSCLC).

Dr. Sklar on Challenges With Clinical Trials in Bladder Cancer

February 7th 2017

Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses some of the challenges that come with conducting clinical trials in the treatment of patients with bladder cancer.

Dr. Figlin on the Plethora of Novel Agents in RCC

February 7th 2017

Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology and associate director of academic program development in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses the major novel agents at the forefront of the treatment landscape of renal cell carcinoma.